What is the risk for prostate cancer from transdermal testosterone treatment for hypogonadism?

Updated: Apr 03, 2019
  • Author: Maria G Vogiatzi, MD; Chief Editor: George T Griffing, MD  more...
  • Print
Answer

In a 6-year European study of men being treated for hypogonadism, long-term transdermal testosterone treatment did not increase prostate-specific antigen (PSA) levels or influence prostate cancer risk. [4, 5]

Investigators used data from a 5-year, open-label extension of a 1-year trial of a transdermal testosterone patch (Testopatch) in men with hypogonadism. Study subjects wore two 60 cm2 patches, each of which delivered 2.4 mg of testosterone per day. More than 90% of patients had PSA concentrations below 2 ng/mL during the 6-year study, and no prostate cancer was found in patients over the course of the trial.

See Treatment and Medication for more detail.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!